PromoCell announces services for large-scale industrial lots of Mesenchymal Stem Cells

New services for large-scale industrial lots allows customers to have high volumes of standardized MSC populations derived from bone marrow and adipose tissue.

PromoCell announces services for the large-scale industrial lots of human mesenchymal stem cells (hMSCs). As a leading manufacturer of stem cell research products, PromoCell has over a decade of experience in the production of mesenchymal stem cells derived from bone marrow, umbilical cord and adipose tissue that ensure the highest level of standardization in accordance with ISCT* guidelines. With the growing demand for highly standardized MSC populations in cell-based therapy applications, PromoCell has now introduced their large-scale production service for mesenchymal stem cells derived from bone marrow and adipose tissue. The cells are offered as industrial lots that guarantee the access to a huge number of cells from the same lot with same specifications and quality.

Mesenchymal stem cells, also termed mesenchymal stromal cells, are multipotent cells that can differentiate into a variety of cell types and have the capacity for self-renewal. MSCs are capable of differentiating into different cell types e.g. adipocytes, chondrocytes, osteoblasts, myocytes, neurons, hepatocytes, and pancreatic islet cells and many more. Due to their relevant immunomodulatory properties, mesenchymal stem cells have received great attention in recent years with regard to their usage in cellular therapies.

“With significant sales and growing interest in mesenchymal stem cell applications throughout the world, we have taken an important step to offer services for large-scale industrial lots readily available to our customers’’ says Dr. Irma Boercsoek, COO of PromoCell.

Large-scale MSC production processes are a prerequisite for the commercial and clinical translation of cell-based therapies. A key requirement for this is the maintenance of a highly uniform cell population that retains all key characteristics of MSCs in a tightly defined manner. Meeting these requirements demands the highest degree of expertise in cell isolation, media manufacturing and quality control. By introducing large-scale industrial lots of MSCs that meet these criteria, PromoCell further enables the advancement of cell-based research applications.

Optimized PromoCell media are available to support both the growth of MSCs and their differentiation into several different lineages. ‘’Our brand stands for more than 29 years of expertise and a proven reputation in the production of world-class human cell culture products’’ adds Dr. Christian Gojak, Head of Marketing at PromoCell. Combined with its reliable profile and excellent scientific support, PromoCell offers researchers an efficacious solution to support consumer needs.

To learn more about PromoCell’s services for large-scale industrial lots of Mesenchymal Stem Cells, contact us via this online form or get in touch with scientific support service at the toll-free number 0800 – 776 66 23.

*ISCT (International Society for Cellular Therapy) Cytotherapy (2006) Vol. 8, No. 4, 315-317

Have a question? Ask one of our highly qualified PhD scientists

The best product is the one that’s tailored to your needs. We own our entire manufacturing process, so we can create customized products for clients in a huge range of markets worldwide.

Contact Us

Choose your Region

Please choose your region for an optimized website experience. So we can provide you with the most useful information for your country.

  1. North America
    1. Canada
    2. United States
  2. Europe
    1. Austria
    2. Belgium
    3. Bulgaria
    4. Croatia
    5. Czech Republic
    6. Denmark
    7. Finland
    8. France
    9. Germany
    10. Greece
    11. Hungary
    12. Ireland
    13. Italy
    14. Liechtenstein
    15. Luxembourg
    16. Monaco
    17. Netherlands
    18. Norway
    19. Poland
    20. Portugal
    21. Romania
    22. Slovakia
    23. Slovenia
    24. Spain
    25. Sweden
    26. Switzerland
    27. United Kingdom
  3. Asia
    1. India
    2. Indonesia
    3. Israel
    4. Japan
    5. Malaysia
    6. Singapore
    7. South Korea
    8. Taiwan
    9. Thailand
Scroll to top